Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc.…
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
In connection with Mr. Sylvain’s promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the “Offer Letter”) providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan, to participate in the Company’s Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.
Biographical and other information for Mr. Sylvain is set forth in Dexcom’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2026, and is incorporated herein by reference. There is no arrangement or understanding between Mr. Sylvain and any other persons pursuant to which such person was selected as an officer. There are no family relationships among any of Dexcom’s directors or executive officers and Mr. Sylvain, and Mr. Sylvain does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the Offer Letter, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Item 7.01Item 7.01 - Regulation FD Disclosure
ITEM 7.01. REGULATION FD DISCLOSURE.
On September 14, 2026, Dexcom announced the promotion of Mr. Sylvain in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.